Latest Listings And Ipos News

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Vinyl Group Ltd has reported a robust 49% increase in revenue for the first half of FY26, alongside a significant reduction in net loss, driven by strategic acquisitions and AI integration.

Codeifai Limited reported a 26% revenue decline to $598,497 for 2025 alongside a sharp increase in net loss to $6.22 million, driven by strategic investments and market challenges. The company’s pivot to self-service SaaS platforms, including a key acquisition post-year-end, signals a transformative but uncertain path forward.

Advanced Energy Minerals reports a sharp revenue increase alongside a substantial net loss for 2025, completing a major plant expansion and raising $44.8 million in its IPO.

Uscom Limited has completed the sale of all its international subsidiaries, recording a significant gain but ceasing trading activities and remaining suspended on the ASX. The company now aims to secure a new business to resume operations.

Fat Prophets Global Contrarian Fund Ltd reported a dramatic turnaround with a $9.3 million profit for the half-year ended December 2025, up from just $14,000 a year earlier, alongside a declared interim dividend.

Thorney Opportunities Ltd has returned to profitability with a $6.55 million net profit for the half-year ending December 2025, declaring a fully franked interim dividend and continuing its share buy-back program.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Clime Investment Management reports a strong half-year operating profit surge and proposes a fully franked interim dividend, while streamlining its business to target sophisticated investors.

Atomos Limited has reported a profitable first half of FY26 with revenue up 28%, driven by strong sales and cost discipline. The company reaffirms its full-year guidance, anticipating further growth and positive cash flow in the second half.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.